Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2026
AstraZeneca and Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca and Daiichi Sankyo have partnered with Summit to test a cancer drug combination, as reported by Reuters.
2026
Daiichi Sankyo ifinatamab filing withdrawal
A Yahoo Finance article headline attributes an ifinatamab filing withdrawal to Daiichi Sankyo Company (TSE:4568) and uses it as the news peg for a valuation piece asking whether the company is undervalued. The supplied evidence is the headline only and does not specify the regulator, market, or date of the withdrawal.
2021
Daiichi Sankyo reportedly carries out layoffs
The article reports that Daiichi Sankyo was carrying out layoffs affecting its anti-infective and respiratory analgesic product lines, with affected employees mainly outside Beijing, Shanghai and Guangzhou.
2021
ENHERTU receives Japan Techno-Economics Society Prime Minister's Award
Daiichi Sankyo announced that ENHERTU received the Prime Minister's Award at the 9th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society.
2020
Daiichi Sankyo launches ENHERTU in Japan
Daiichi Sankyo announced the launch of ENHERTU (trastuzumab deruxtecan) in Japan for patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, subject to the stated treatment limitations.
2019
Daiichi Sankyo files declaratory judgment action against Seattle Genetics
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi’s filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other’s claims to the technology.